Diana Odhiambo

Dec 14, 2023 | redjournal.org | Diana Odhiambo |Allison Pittman |Alex Bassil |Joshua Chen

ABSTRACT Despite aggressive multimodal treatment that typically includes definitive or adjuvant radiation therapy (RT), locoregional recurrence rates approach 50% for patients with locally advanced human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC). Thus, more effective therapeutics are needed to improve patient outcomes. We evaluated the radiosensitizing effects of ATR inhibitor (ATRi) BAY 1895344 in preclinical models of HNSCC.